Cell therapy in corneal endothelial disease

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Cell Biology

Background:

• Endothelial keratoplasty is the standard treatment for corneal endothelial diseases, but faces limitations in donor tissue availability and global accessibility.
• Cell therapy presents a promising alternative, with early research indicating significant potential for treating corneal blindness.
• Corneal endothelial diseases affect numerous individuals worldwide, highlighting the need for innovative therapeutic strategies.

Purpose of the Study:

• To review the latest advancements in cell therapy for corneal endothelial diseases.
• To summarize recent findings on the efficacy of cell-based treatments in preclinical models.
• To discuss the potential of cell therapy to address limitations of current treatments.

Main Methods:

• Review of recent scientific literature on cell therapy for corneal endothelial diseases.
• Highlighting studies utilizing human embryonic stem cells, induced pluripotent stem cells, and cadaveric corneal endothelial cells (CECs).
• Examination of corneal endothelial progenitor cells, cryopreserved cell viability, and non-cultured cell efficacy.

Main Results:

• Successful functional outcomes reported in animal models using various cell types for intracameral injection.
• Demonstrated potential of corneal endothelial progenitors, cryopreserved cells, and non-cultured cells in treating corneal decompensation.
• Advancements in understanding corneal endothelial cell (CEC) physiology and cell therapy administration.

Conclusions:

• Cell therapy is rapidly evolving as a viable treatment for corneal endothelial diseases.
• Ongoing research offers hope for a scalable solution to corneal blindness globally.
• The field is progressing towards overcoming donor tissue limitations and improving patient access to treatment.